| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11364224 | UPSHER SMITH LABS | Pharmaceutical composition for treating migraine |
Jan, 2036
(12 years from now) | |
| US10537554 | UPSHER SMITH LABS | Pharmaceutical composition for treating migraine |
Jan, 2036
(12 years from now) | |
Zembrace Symtouch is owned by Upsher Smith Labs.
Zembrace Symtouch contains Sumatriptan Succinate.
Zembrace Symtouch has a total of 2 drug patents out of which 0 drug patents have expired.
Zembrace Symtouch was authorised for market use on 28 January, 2016.
Zembrace Symtouch is available in solution;subcutaneous dosage forms.
Zembrace Symtouch can be used as treatment of migraine.
The generics of Zembrace Symtouch are possible to be released after 29 January, 2036.
Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient
Market Authorisation Date: 28 January, 2016
Treatment: Treatment of migraine
Dosage: SOLUTION;SUBCUTANEOUS
ZEMBRACE SYMTOUCH family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic